KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Debt (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Non-Current Debt for 16 consecutive years, with $15.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt fell 6.35% year-over-year to $15.0 billion, compared with a TTM value of $15.0 billion through Dec 2025, down 6.35%, and an annual FY2025 reading of $15.0 billion, down 6.35% over the prior year.
  • Non-Current Debt was $15.0 billion for Q4 2025 at Teva Pharmaceutical Industries, down from $16.8 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $22.3 billion in Q1 2021 and bottomed at $15.0 billion in Q4 2025.
  • Average Non-Current Debt over 5 years is $18.5 billion, with a median of $18.5 billion recorded in 2022.
  • The sharpest move saw Non-Current Debt decreased 15.68% in 2024, then rose 2.23% in 2025.
  • Year by year, Non-Current Debt stood at $21.6 billion in 2021, then fell by 11.63% to $19.1 billion in 2022, then decreased by 4.93% to $18.2 billion in 2023, then dropped by 11.89% to $16.0 billion in 2024, then dropped by 6.35% to $15.0 billion in 2025.
  • Business Quant data shows Non-Current Debt for TEVA at $15.0 billion in Q4 2025, $16.8 billion in Q3 2025, and $16.8 billion in Q2 2025.